Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.
Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com
Pfizer announced on July 24, 2025 that it has completed its licensing agreement with 3SBio that grants Pfizer with the exclusive rights to develop, manufacturing, and commercialize SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, which was developed using 3SBio’s proprietary CLF2 platform. The licensing agreement enhances Pfizer’s oncology portfolio by providing the company with a potential candidate treatment for a variety of cancers.
3SBio will receive $1.25 billion in payment as part of the agreement, with Pfizer investing $100 million equity in 3SBio. Pfizer will also have the option to extend the license to exclusive development and commercialization rights for SSGJ-707in China, which would cost Pfizer $150 million in option payments.
Monotherapy for patients with advanced NSCLC
SSGJ-707, which is under clinical trials, targets non-small cell lung cancer (NSCLC), metastatic colorectal cancer, and gynecological tumors. According to Pfizer, interim Phase II clinical trial results show SSGJ-707 is safe and effective as a monotherapy for patients with advanced NSCLC. These results were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
Pfizer will manufacture drug substance for SSGJ-707 at its Sanford, NC plant and drug product at its McPherson, Kan. facility. Clinical development trial sites will be located across the United States and the rest of the world, and Phase III clinical development for NSCLC and other solid tumors will be a priority.
“We are excited to contribute our significant expertise and resources to advance rapidly the development of the SSGJ-707 program including novel combination strategies across a number of our major tumor areas of focus,” said Chris Boshoff, MD, PhD, chief scientific officer and president, Research & Development, Pfizer, in a press release (1). “This is an important candidate that combines two key targets in a promising class of medicines, complementing our antibody-drug conjugate portfolio and further demonstrates our commitment to advancing pioneering science to deliver transformative cancer medicines and new hope to people living with cancer.”
Pfizer Oncology’s pipeline includes small molecules, antibody-drug conjugates, and bispecific antibodies that target breast cancer, genitourinary cancer, hematology-oncology, and thoracic cancers.
Pfizer’s prostate cancer treatment sees positive results
Earlier in July, Pfizer and Astellas Pharma announced that their androgen receptor inhibitor-based regimen, enzalutamide (XTANDI), demonstrated overall survival benefit in non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical recurrence (BCR) in a Phase III EMBARK study (2).
“These data demonstrate that treatment with XTANDI can extend life for men with nmHSPC and high-risk BCR who have relapsed after initial curative-intent therapy with prostatectomy, radiation therapy or both, further validating EMBARK’s metastasis-free survival (MFS) data,” said Neal Shore, MD, F.A.C.S, START Carolinas/Carolina Urologic Research Center, in the press release (2). “While men with nmHSPC with high-risk BCR now have expanded treatment choices, these results demonstrate a clear clinical benefit, including both MFS and OS, supporting the clinical practice of initiating XTANDI for these patients.”
“XTANDI is the only androgen receptor inhibitor-based regimen to demonstrate a survival benefit in metastatic HSPC and nmHSPC with high-risk BCR, as well as castration-resistant prostate cancer, highlighting its significant patient impact in advanced prostate cancer,” said Johanna Bendell, MD, oncology chief development officer, Pfizer, in the release. “These positive results add to the robust clinical support for the use of XTANDI and broaden clinical confidence, offering men with high-risk BCR evidence that they might live longer when they start XTANDI early.”
References
- Pfizer. Pfizer Completes Licensing Agreement with 3SBio. Press Release. July 24, 2025. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-licensing-agreement-3sbio
- Pfizer. XTANDI Plus Leuprolide Significantly Improves Survival Outcomes in Men with Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence. Press Release. July 10, 2025. https://www.pfizer.com/news/press-release/press-release-detail/xtandir-plus-leuprolide-significantly-improves-survival
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
